Press

Transcend Therapeutics and Yale awarded U.S. Department of Defense grant to study methylone for PTSD

Sep 21 • 2 min read

Company also announces that the IMPACT-1 clinical trial is underway with open-label results expected in the coming months Transcend Therapeutics, a biotechnology company developing rapid-acting treatments for neuropsychiatric diseases, announced receipt of a collaborative grant award with Yale University to support first-of-its-kind preclinical research on methylone – Transcend’s lead compound for the treatment of post-traumatic stress disorder…

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Sep 21 • 3 min read

Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with…

Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

Sep 21 • 4 min read

–Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2 data for pivotal studies – – Breakthrough Therapy designation anticipated in late 2023, subject to FDA approval – – Previously announced acquisition of Small Pharma Inc. expected to close in…

Filament Health and Jaguar Health Joint Venture Magdalena Biosciences Completes Import of Coca Leaf From Peru

Sep 21 • 4 min read

The import to Filament’s Metro Vancouver facility was conducted in collaboration with the Peruvian government and facilitated by Filament Health and Jaguar Health Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or “Filament Health”), a clinical-stage natural psychedelic drug development company, today announced that Magdalena Biosciences (“Magdalena”), a joint venture formed by Filament and Jaguar Health, Inc. (Nasdaq: JAGX) (“Jaguar…

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Sep 20 • 3 min read

Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with the preparation of a pre-Investigational New Drug (IND) package and meeting request with the United…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441